Managing adherence, exposure, and toxicity in oral anticancer therapies

被引：0
|
作者：
Kazuo Kobayashi [1 ]
机构：
[1] The Cancer Institute Hospital of JFCR,Department of Pharmacy
来源：
Journal of Pharmaceutical Health Care and Sciences | / 11卷 / 1期
关键词：
Oral anticancer agents; Adherence; Occupational exposure; Hand-foot skin reaction; Hypothyroidism; Pharmacist intervention; Medication safety; Oncology pharmacy; Patient education; Adverse effect management;
D O I：
10.1186/s40780-025-00437-2
中图分类号：
学科分类号：
摘要：
The management of adherence, exposure risk, and adverse effects in oral anticancer agents (OAAs) is essential for optimizing patient outcomes in oncology pharmacy. This review highlights key efforts to enhance adherence, reduce occupational exposure, and improve adverse effect management in OAA therapy.
引用
收藏
相关论文
共 50 条
  • [41] Interventions to support adherence to oral anticancer therapies: research challenges, lessons learned, and strategies to overcome them from Australia and Switzerland
    Carole Bandiera
    Xiomara Skrabal Ross
    Evelina Cardoso
    Dorothea Wagner
    Chantal Csajka
    Ian Olver
    Pandora Patterson
    Vijayaprakash Suppiah
    Kate M. Gunn
    Marie Schneider
    Supportive Care in Cancer, 2022, 30 : 3655 - 3659
  • [42] Interventions to support adherence to oral anticancer therapies: research challenges, lessons learned, and strategies to overcome them from Australia and Switzerland
    Bandiera, Carole
    Ross, Xiomara Skrabal
    Cardoso, Evelina
    Wagner, Dorothea
    Csajka, Chantal
    Olver, Ian
    Patterson, Pandora
    Suppiah, Vijayaprakash
    Gunn, Kate M.
    Schneider, Marie
    SUPPORTIVE CARE IN CANCER, 2022, 30 (05) : 3655 - 3659
  • [43] EXPOSURE LEVELS AND ORAL TOXICITY OF SURFACTANTS
    SWISHER, RD
    ARCHIVES OF ENVIRONMENTAL HEALTH, 1968, 17 (02): : 232 - +
  • [44] Novel Multitargeted Anticancer Oral Therapies: Sunitinib and Sorafenib as a Paradigm
    Sulkes, Aaron
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2010, 12 (10): : 628 - 632
  • [45] Interaction screening of therapies with oral anticancer medicines: a retrospective evaluation
    Van Laethem, K.
    Vermis, K.
    Lesage, D.
    Rottey, S.
    Somers, A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (01) : 231 - 232
  • [46] ONS GuidelinesTM to Support Patient Adherence to Oral Anticancer Medications
    Belcher, Sarah M.
    Mackler, Emily
    Muluneh, Benyam
    Ginex., Pamela K.
    Anderson, Mary K.
    Bettencourt, Elizabeth
    DasGupta, Ryan K.
    Elliott, Jennifer
    Hall, Erica
    Karlin, Michelle
    Kostoff, Diana
    Marshall, Victoria K.
    Millisor, Vanessa E.
    Molnar, Maegan
    Schneider, Susan M.
    Tipton, Janelle
    Yackzan, Susan
    LeFebvre, Kristine B.
    Sivakumaran, Kapeena
    Waseem, Haya
    Morgan, Rebecca L.
    ONCOLOGY NURSING FORUM, 2022, 49 (04) : 279 - 295
  • [47] Mobile Health in Adherence to Oral Anticancer Drugs A Scoping Review
    Gambalunga, Francesca
    Iacorossi, Laura
    Notarnicola, Ippolito
    Serra, Valeria
    Piredda, Michela
    De Marinis, Maria Grazia
    CIN-COMPUTERS INFORMATICS NURSING, 2021, 39 (01) : 17 - 23
  • [48] ORAL ANTICANCER MEDICATIONS: IMPROVING CONSENT AND ADHERENCE ASSESSMENT PROCESSES
    La Touche, Amiee
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [49] Adherence enhancing interventions for oral anticancer agents: A systematic review
    Mathes, Tim
    Antoine, Sunya-Lee
    Pieper, Dawid
    Eikermann, Michaela
    CANCER TREATMENT REVIEWS, 2014, 40 (01) : 102 - 108
  • [50] Financial toxicity of oral therapies in advanced prostate cancer
    Joyce, Daniel D.
    Dusetzina, Stacie B.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (09) : 363 - 368
12345